NEOVII Biotech

Name

NEOVII Biotech

Legal name

Neovii Pharmaceuticals AG

Website

https://neovii.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Immunosuppressive Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

Keywords

• Polyclonal antibody therapy
• Immunosuppressive biopharmaceuticals
• Transplantation medicine
• Hematology oncology drugs
• Biologic immunosuppressants

Headquarters

HQ city

Gräfelfing

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Neovii generates revenue through the manufacture and sale of its proprietary pharmaceutical products, primarily Grafalon, which is distributed globally through prescription-only channels to hospitals and transplant centers. The company operates as a fully integrated pharmaceutical company covering the entire value chain from sourcing and development through manufacturing to distribution, marketing, and sales.
2. Licensing and Milestone Revenue: Under the exclusive agreement with Fosun Pharma, Neovii receives upfront payments, regulatory and commercial sales milestones, as well as proceeds from supplying Grafalon to the partner for the China market.
3. Distribution and Supply Agreements: Neovii supplies Grafalon through distribution agreements with regional partners, requiring minimum order values of EUR 5,000 per order and minimum order quantities of 100 vials for the product.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

NEOVII Biotech is a fully integrated biopharmaceutical company that develops, manufactures, and commercializes immunosuppressive polyclonal antibody therapies. Its flagship product, Grafalon (Rabbit anti-human T-lymphocyte globulin, ATLG), is a polyclonal antibody therapy used in solid organ transplantation and allogeneic stem cell transplantation to prevent graft rejection and graft-versus-host disease (GVHD), and is approved in more than 40 countries. The company covers the entire value chain from sourcing and development through GMP manufacturing to global distribution, marketing, and sales.

Product overview

NEOVII Biotech is a fully integrated biopharmaceutical company specializing in immunosuppressive polyclonal antibody therapies. The core product is Grafalon (Rabbit anti-human T-lymphocyte globulin, ATLG), a polyclonal antibody used in organ transplantation and stem cell transplantation to prevent graft-versus-host disease and organ rejection. The product portfolio includes the marketed Grafalon available in 40+ countries with over 250,000 treated patients, the clinical-stage therapy NB-15 for MNGIE, and a COVID-19 vaccine research program developed with Tel Aviv University.

Differentiator

Problem solved

Functional benefit

Brands

• Grafalon: Neovii's proprietary medicinal product (rabbit anti-human T-lymphocyte globulin, ATLG), previously known as ATG-Fresenius-S, used in transplantation medicine and approved in over 40 countries

Products and services

• Grafalon (Rabbit anti-human T-lymphocyte globulin, ATLG) Polyclonal antibody immunosuppressive therapy used to prevent graft rejection in solid organ transplantation and to prevent graft-versus-host disease (GVHD) in allogeneic stem cell transplantation. Also approved in selected countries for treatment of aplastic anemia. Supplied as a sterile concentrate (20mg/ml, 5ml vial) to hospitals, transplant centers, and hematology/oncology departments on a prescription-only basis. Holds FDA orphan drug status and fast track designation for prevention of GVHD in the United States.

Quantifiable outcome

• Over 250,000 patients treated with Grafalon with 30+ years of clinical experience
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• DKMS (Deutsche Knochenmarkspenderdatei)minorStrategic or Co-development Partner · 17 June 2026DKMS published a press release on the GRAPPA study, a large randomized controlled trial presented at the European Hematology Association (EHA) Congress 2026 in Stockholm. The study provides new clinical evidence that ATG remains standard of care for GVHD prophylaxis in HLA-compatible unrelated donor hematopoietic cell transplantation.
• Fosun Pharma (Shanghai Fosun Pharmaceutical Industry Development Co. Ltd)coreChannel Partner/ Reseller/ Distributor · 7 September 2022Neovii granted Fosun Pharma an exclusive license to develop and commercialize Grafalon in Mainland China, Hong Kong SAR, Macau SAR, and Taiwan region. The agreement includes upfront, regulatory, and commercial sales milestones plus product supply revenue. The partnership aims to expand Grafalon's position in transplantation medicine, achieve regulatory alignment with global approvals for stem cell transplant, and explore expansion into auto-immune and onco-hematology conditions. The agreement also sets the foundation to expand cooperation to additional Neovii products including NB-15 for MNGIE.
• Ramot / Tel Aviv UniversityminorStrategic or Co-development Partner · 12 May 2020Neovii signed a research and license agreement with Ramot (Tel Aviv University's technology transfer company) and a team led by Prof. Jonathan Gershoni to develop a novel COVID-19 vaccine using an epitope-based platform targeting the Receptor Binding Motif (RBM) of the coronavirus spike protein. Neovii received exclusive rights to develop and commercialize the vaccine technology. The collaboration leveraged Neovii's expertise in passive polyclonal antibody development and manufacturing.
• Neopharm GroupcoreOthersNeovii is a member of the Israel-based Neopharm Group, which is engaged in research, development, and commercialization of pharmaceutical, medical, and consumer healthcare products with revenues exceeding $500 million and more than 1,000 employees worldwide.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sanofi (Genzyme): Sanofi markets Thymoglobulin (anti-thymocyte globulin, ATG), the most direct competing polyclonal antibody product to Grafalon used in transplant immunosuppression. Closely comparable in therapeutic class, manufacturing complexity, and customer base of transplant centers.
• Astellas Pharma: Astellas markets Prograf (tacrolimus), a cornerstone immunosuppressant used alongside ATG in solid organ transplantation. Directly comparable as a transplant-focused specialty biopharma serving the same hospitals and transplant centers.

Emerging players

• Veloxis Pharmaceuticals: Veloxis markets Envarsus XR (tacrolimus), a transplant immunosuppressant competing in the same post-transplant maintenance segment as Neovii's Grafalon-adjacent regimen. Comparable in addressing transplant patient populations with specialty pharma commercial models.

Broad incumbents

• CSL Behring: CSL Behring is a global specialty biologics manufacturer with a transplant and immunology portfolio (including specialty plasma-derived therapies). Comparable as a fully integrated specialty biologics company with hospital-channel distribution.
• Pfizer: Pfizer markets transplant and oncology specialty products (historically including sirolimus and broader immunosuppressant portfolios) and has the hospital specialty sales infrastructure to compete with Neovii in transplantation. Comparable as a broad biopharma with transplant presence.
• Bristol Myers Squibb: BMS markets Nulojix (belatacept) for kidney transplant rejection prophylaxis and has a strong hematology/oncology franchise (including post-transplant indications). Comparable as a broad biopharma competitor in the same transplant specialty market.
• Novartis: Novartis markets everolimus (Certican/Zortress) for transplant immunosuppression and has broader oncology/hematology adjacencies. Comparable as a broad biopharma with transplant and onco-hematology franchises where Neovii also plays.

Regional players

• Hansoh Pharmaceutical Group: Hansoh is a leading Chinese specialty biopharma with growing transplant and hematology presence. Relevant as a regional incumbent with overlapping therapeutic categories in the same China market where Neovii's Fosun partnership is launching Grafalon.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neovii-biotech-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NEOVII Biotech